Deal Announcements

Xencor Adds $15 Million To Fifth Round

Friday, October 26, 2007 5:00:00 AM PDT | VentureDeal Staff

MONROVIA, CA -- Biopharmaceutical company Xencor said that it has closed its series E round with an additional $15 million in venture capital investment.

Xencor is developing a pipeline of antibodies for cancer and protein therapeutics for inflammation and autoimmune diseases.  The company's partners include Genentech and Eli Lilly.

Investors in the round included Oxford Bioscience Partners, Merlin Nexus and Novo A/S.  The company said it will use the proceeds to advance its XmAB antibody drug candidates.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1